Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Download Data

Milestone Pharmaceuticals Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2024: USD -868.00 K

Milestone Pharmaceuticals Inc Revenue is USD -868.00 K for the Trailing 12 Months (TTM) ending March 31, 2024, a -114.47% change year over year. The revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Milestone Pharmaceuticals Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 6.00 M, a -86.67% change year over year.
Milestone Pharmaceuticals Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 45.00 M, a 0.00% change year over year.
Milestone Pharmaceuticals Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
Milestone Pharmaceuticals Inc Revenue for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 0.00, a 0.00% change year over year.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends